Most patent searches miss the real fight.
If youve ever run a keyword-only prior art search, you already know the uncomfortable truth: youre not finding what mattersyoure finding what you can name.
In pharma and biotech, that gap can be the differenc…

Designing Around Formulation Patents: The Quiet Competitive Edge in Pharma IP
In pharma, the loudest battles often happen in the courtroom. But the most valuable wins frequently happen earlieron the whiteboard, in the lab, and in the IP strategy memo t…

Formulation Forensics: The Hidden Clues in Drug Patent Claims (and Why They Matter to Investors)
Most people read drug patents like legal documents.
Smart investors read them like investigative reports.
Because buried in the fine printespecially in for…

The Biosimilar Patent Dance Isnt a Game of LuckIts a Game of Timing, Strategy, and Evidence
If youre a biologics innovator or a biosimilar applicant, you already know the headline: the patent dance can decide years of market exclusivity, launch timing,…

Generic winners dont wait for exclusivitythey engineer it.
In the Paragraph IV world, the 180-day exclusivity clock isnt just a deadline. Its a strategic assetone that can be won, preserved, and monetized only if the generic manufacturer treats litig…

The Patent Dance Is No Longer a ChoreographyIts a Strategy War. Heres the Playbook.
If youre a biologics or biosimilar applicant, you already know the patent dance isnt a formality. Its the first real battlefield where timing, leverage, and litigation …

Big Pharma loves to talk about pipelines. But the real forecasting edge is hiding in the supply chaininside the unglamorous, spreadsheet-heavy world of drug patent data.
Heres the uncomfortable truth: most demand forecasts are built on whats already se…

Patent cliffs dont just hit revenuethey hit supply chains.
When a blockbuster drugs exclusivity ends, the market doesnt simply open. It reprices, reallocates, and re-routesoften faster than procurement teams can react. The result is familiar: sudden …

Generic drug makers are facing a quiet margin crisisand its not coming from competition alone. Its coming from the math: the cost to keep plants running, the cost to defend product lines, the cost to navigate regulatory friction, and the cost of winnin…

Branded pharmas revenue model is under siegeand its not just one problem. Its a stack.
In a recent piece from DrugPatentWatch, the argument is blunt: there are multiple brutal problems that are systematically eroding the traditional branded revenue eng…